MedPath

Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

Completed
Conditions
Asthma
Registration Number
NCT00523679
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program.
Read More
Exclusion Criteria
  • Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇰🇷

Seoul, Songpa-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath